Details For Selected Brain Tumor Treatment

Sponsored By

Cedars-Siani Medical Center Brain Tumor Program

Please Click On The Above Banner For More Details

Back to New Treatments List


		Treatment Name:		A Phase II Study of HLA-Matched Peripheral Blood Stem Cell Transplantation for Metastatic Renal Cell Carcinoma as Adoptive Allogeneic Immunotherapy

		Phase:		Phase 2

		Treatment ID#:		1615 NCT00001635

		Age Group:		Adults Only

		Min Karnofsky Score:		40: Requires special care and assistance; disabled

		Conditions:		Prior Surgery is Allowed Prior Radiation is Sometimes Allowed Prior Chemotherapy is Allowed Diagnosis of stage IIIA or IIIB non-small cell lung cancer Complete response, partial response, or stable disease after definitive locoregional therapy (thoracic radiotherapy) with or without systemic chemotherapy and/or surgery (chemotherapy alone is not considered definitive therapy) No more than 16 weeks since prior therapy No progressive disease No extracranial distant metastatic disease No suspicion of CNS metastases by MRI or CT scan

		Last Updated:		11/06/2005

		Tumor Types:		Metastatic Brain Tumor


		Comments:

		Treatment Type:

		Contact:		Diane Heaton MD LaFortune Cancer Center at St. John Health System Tulsa, OK 74104 USA Phone: 918-744-2071 Fax: E-mail: Website:

Last updated refers to the date when our listing for each treatment was last updated.
ID is a combination of our internal ID and the official ID for the trial, if any.
Min Karnofsky is a general guide to how well you have to function to use this treatment

Translate this pageMicrosoftÂ® Translator

Copyright (c) 1993 - 2009 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740

Website Design By